Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.63 |
| ▸ | RAB9A | P51151 | 5/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8880347 | 0.86 | MAPT (0.52) | SMN1; SMN2RAB9AKDM4EMEN1KMT2A | |
| SCHEMBL13363878 | 0.86 | CYP46A1 (0.49) | SMN1; SMN2RAB9AKDM4EMEN1KMT2A | |
| SCHEMBL15919469 | 0.86 | MAPT (0.60) | SMN1; SMN2RAB9AKDM4EMEN1KMT2A | |
| SCHEMBL20507127 | 0.85 | MAPT (0.56) | SMN1; SMN2RAB9AKDM4EMEN1KMT2A | |
| SCHEMBL30516592 | 0.85 | CYP19A1 (0.51) | SMN1; SMN2RAB9AKDM4EMEN1KMT2A | |
| SCHEMBL13363888 | 0.85 | CYP19A1 (0.51) | SMN1; SMN2RAB9AKDM4EMEN1KMT2A | |
| SCHEMBL17652591 | 0.84 | MAPT (0.60) | SMN1; SMN2RAB9AKDM4EMEN1KMT2A | |
| SCHEMBL2724085 | 0.84 | SMN1; SMN2 (0.66) | SMN1; SMN2RAB9AKDM4EMEN1KMT2A | |
| SCHEMBL1544560 | 0.84 | MAPT (0.55) | SMN1; SMN2RAB9AALDH1A1GAAMAPT | |
| SCHEMBL214283 | 0.84 | MEN1 (0.49) | SMN1; SMN2RAB9AKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240139158-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | PROTEOSTASIS THERAPEUTICS INC (US) | 2024-05-02 | — | — | US | disclosed |
| EP-3237411-B1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20220175735-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | PROTEOSTASIS THERAPEUTICS INC (US) | 2022-06-09 | — | — | US | disclosed |
| US-20220175735-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | PROTEOSTASIS THERAPEUTICS INC (US) | 2022-06-09 | — | — | US | disclosed |
| CN-107207487-B | Compounds, compositions and methods for increasing CFTR activity | 蛋白质平衡治疗股份有限公司 | 2021-12-28 | — | — | CN | disclosed |
| US-11083709-B2 | Compounds, compositions, and methods of increasing CFTR activity | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-11083709-B2 | Compounds, compositions, and methods of increasing CFTR activity | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20200360348-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2020-11-19 | — | — | US | disclosed |
| US-20200360348-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2020-11-19 | — | — | US | disclosed |
| US-20200190072-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2020-06-18 | — | — | US | disclosed |
| US-20160128984-A1 | ISOXAZOLE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB, LLC | 2016-05-12 | — | — | US | disclosed |
| US-20160128984-A1 | ISOXAZOLE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB, LLC | 2016-05-12 | — | — | US | disclosed |
| US-20160128984-A1 | ISOXAZOLE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB, LLC | 2016-05-12 | — | — | US | disclosed |
| WO-2016054560-A1 | ISOXAZOLE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2016-04-07 | — | — | WO | disclosed |
| WO-2016054560-A1 | ISOXAZOLE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2016-04-07 | — | — | WO | disclosed |
| WO-2014160668-A1 | TETRAHYDROISOQUINOLINES CONTAINING SUBSTITUTED AZOLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-10-02 | — | — | WO | disclosed |
| EP-2691379-A1 | HERBICIDALLY AND FUNGICIDALLY ACTIVE 3-PHENYLISOXAZOLINE-5-CARBOXAMIDES AND 3-PHENYLISOXAZOLINE-5-THIOAMIDES | Bayer Intellectual Property GmbH (DE) | 2014-02-05 | — | — | EP | disclosed |
| WO-2012130798-A1 | HERBICIDALLY AND FUNGICIDALLY ACTIVE 3-PHNEYLISOXAZOLINE-5-CARBOXAMIDES AND 3-PHNEYLISOXAZOLINE-5-THIOAMIDES | BAYER CROPSCIENCE AG (DE) | 2012-10-04 | — | — | WO | disclosed |
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240139158-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | SMPD1, ELANE, SMPD2 | SMN1; SMN2 1913/4885RAB9A 1690/4885KDM4E 4489/4885 |
| US-20200360348-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF INCREASING CFTR ACTIVITY | CFTR, ABCB4, SCNN1B | SMN1; SMN2 3701/4885RAB9A 840/4885KDM4E 4684/4885 |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | SMN1; SMN2 3894/4885RAB9A 20/4885KDM4E 4305/4885 |
| US-20200190072-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | CFTR, SCNN1B, SCNN1G | SMN1; SMN2 4744/4885RAB9A 715/4885KDM4E 4657/4885 |
| US-20160128984-A1 | ISOXAZOLE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SERPINB1, ELANE | SMN1; SMN2 3370/4885RAB9A 3589/4885KDM4E 4302/4885 |
| US-11083709-B2 | Compounds, compositions, and methods of increasing CFTR activity | CFTR, ABCB4, SCNN1B | SMN1; SMN2 3701/4885RAB9A 840/4885KDM4E 4684/4885 |
| US-20220175735-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | SMPD1, ELANE, SMPD2 | SMN1; SMN2 1913/4885RAB9A 1690/4885KDM4E 4489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.